The recent success of CAR-T cell therapy in hematological tumors has spurred a lot of interest in this field, and rapid progress has occurred in the last 5 years, as evidenced by the approval of multiple CAR-based therapies targeting CD19 and B cell maturation antigen (BCMA) [88, 89, 133]. The gene discussed is CD19; the disease is hematopoietic and lymphoid system neoplasm.